News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
NanoViricides, Inc. reports filing of Annual Report on Form 10-K for fiscal year 2024, financial updates, and plans for Phase II clinical trials of antiviral drug NV-387 -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
NanoViricides, Inc. obtains right of first refusal for antiviral drug developments from TheraCour Pharma, expands drug portfolio with new MOU and revolutionary nanoviricide technology, including NV-387 for multiple viral infections -
-